LIPLASOME PHARMA ApS
CVR 29428514 · Private limited company (ApS) · Active · Low risk
LIPLASOME PHARMA ApS is a Private limited company (ApS), founded on , based in Vejle. The company is registered in the industry forskning og eksperimentel udvikling inden for naturvidenskab og teknik. Our model estimates a bankruptcy risk of 0.0% over the next 12 months, which is 0.0 times the average for Danish companies. 20 annual reports have been published. The latest annual report (31 Dec 2025) shows equity of DKK 2.4m and a net result of DKK 62k.
Bankruptcy risk for LIPLASOME PHARMA ApS
0.0 × the average (1.41%) · higher risk than 6% of active Danish companies
Increases the risk
Reduces the risk
The factors show how often companies with the same characteristic went bankrupt compared with the average (“lift”). The risk is a statistical estimate from a model trained on 141,000+ Danish bankruptcies (AUC 0.93) – not a credit rating. Read about the method.
Company details
- CVR number
- 29428514
- Status
- Active
- Company type
- Private limited company (ApS)
- Founded
- (20 years)
- Address
- Tabletvej 1
7100 Vejle - Municipality
- Vejle
- Industry
- Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000)
Bankruptcies in the industry: Anden forskning og eksperimentel udvikling inden for naturvidenskab og teknik - Share capital
- DKK 92k
- Employees
- 0 (2016)
- Auditor
- EY Godkendt Revisionspartnerselskab
- Audit opted out
- No
Warning signs
| Annual reports filed late | 0 of 20 |
| Missing annual report | No |
| Negative equity | No |
| Equity ratio | 99.5% |
| Current ratio | 19,908% |
| Moves (last 2 years) | 0 |
| CEO changes in total | 0 |
| CEO's previous bankruptcies | 0 |
| Other companies at the address | 52 |
| Going-concern uncertainty | No |
Financials and key figures
| Financial year | 2025 | 2024 |
|---|---|---|
| Gross profit | DKK -28k | DKK -53k |
| Net profit | DKK 62k | DKK -36k |
| Equity | DKK 2.4m | DKK 2.3m |
| Total assets | DKK 2.4m | DKK 2.3m |
| Cash | DKK 302k | – |
| Short-term debt | DKK 12k | – |
| Avg. employees | 0 | – |
Latest annual report: Reporting class B · auditor's statement: Revisionspåtegning · EY Godkendt Revisionspartnerselskab.
Filed annual reports
| Reporting period | Published | Days after period end | |
|---|---|---|---|
| 1 Jan 2025 – 31 Dec 2025 | 88 | ||
| 1 Jan 2024 – 31 Dec 2024 | 90 | ||
| 1 Jan 2023 – 31 Dec 2023 | 113 | ||
| 1 Jan 2022 – 31 Dec 2022 | 104 | ||
| 1 Jan 2021 – 31 Dec 2021 | 96 | ||
| 1 Jan 2020 – 31 Dec 2020 | 85 | ||
| 1 Jan 2019 – 31 Dec 2019 | 107 | ||
| 1 Jan 2018 – 31 Dec 2018 | 91 | ||
| 1 Jan 2017 – 31 Dec 2017 | 75 | ||
| 1 Jan 2016 – 31 Dec 2016 | 69 | ||
| 1 Jan 2015 – 31 Dec 2015 | 71 | ||
| 1 Jan 2014 – 31 Dec 2014 | 132 | ||
| 1 Jan 2013 – 31 Dec 2013 | 148 | ||
| 1 Jan 2012 – 31 Dec 2012 | 156 | ||
| 1 Jan 2011 – 31 Dec 2011 | 150 | ||
| 1 Jan 2010 – 31 Dec 2010 | 156 | ||
| 1 Jan 2009 – 31 Dec 2009 | 168 | ||
| 1 Jan 2008 – 31 Dec 2008 | 168 | ||
| 1 Jan 2007 – 31 Dec 2007 | 163 | ||
| 8 Feb 2006 – 31 Dec 2006 | 149 |
The annual report must reach the Danish Business Authority no later than 5 months after the end of the financial year. We mark reports published more than 6 months after as “late”.
Management, owners and auditor
| Role | Name | From | To |
|---|---|---|---|
| Board | Hans-Henrik Horsted Eriksen | Current | |
| Board | John Riis Mortensen | Current | |
| Board | Sanjay Kumar Sehgal | Current | |
| Board | Torben Brøgger-Mikkelsen | ||
| Board | Holger Bagger-Sørensen | ||
| Board | Ole Lund | ||
| Board | Steen Bagger-Sørensen | ||
| Board | Claus Bagger-Sørensen | ||
| Board | Peter Buhl | ||
| Board | Torben Vilsgaard | ||
| Board | Duncan Moore | ||
| Owner (90%) | BAGGER-SØRENSEN & CO. A/S | Current | |
| Owner (90%) | VECATA INVEST ApS | ||
| Auditor | EY Godkendt Revisionspartnerselskab | Current | |
| Auditor | K P M G C JESPERSEN ÅRHUS I/S | ||
| Founder | Bagger-Sørensen Real Estate A/S | Current | |
| Founder | ZIMBA INVEST ApS | Current | |
| Founder | S.H.A.C.ApS | Current |
Address history (3 moves)
| Tabletvej 1, 7100 Vejle | |
| Lysholt Allé 10, 2., 7100 Vejle | |
| Dandyvej 19, 7100 Vejle | |
| Dandyvej 19, 7100 Vejle |
Former names
| LIPLASOME PHARMA ApS | – now |
| BIO-BEDST ApS | – |
Employees per year
Other companies at the same address
- 4 BEST INVEST ApS Fusioneret
- AI Innovation Center ApS Fusioneret
- ARCEDI BIOTECH ApS Active
- Alkeon ApS Active
- Anpartsselskabet af 2. juni 2022 Fusioneret
- BAGGER-SØRENSEN & CO. A/S Active
- BAGGER-SØRENSEN Real Estate A/S Fusioneret
- BAKODO & CO. ApS Active
- BAKODO ApS Active
- BBS Zimba ApS Active
- BELI 2 ApS Active
- BELI ApS Active
- BMK Defence Systems ApS Active
- BS PROPERTY ApS Fusioneret
- BS Ørum A/S Fusioneret
- BSF Ejendomme ApS Fusioneret
- Bagger-Sørensen Equity A/S Active
- Bagger-Sørensen Real Estate A/S Active
- Baso Group A/S Active
- C. Bagger-Sørensen Invest ApS Active
- CCC3 HOLDING ApS Active
- CHEW INVEST ApS Active
- DANDY Business Park ApS Active
- Daeda ApS Active
- Dandy Business Park Holding ApS Fusioneret
Similar companies in Vejle
- HyperBio Therapeutics ApS Vejle Øst
Questions and answers about LIPLASOME PHARMA ApS
Has LIPLASOME PHARMA ApS gone bankrupt?
No, LIPLASOME PHARMA ApS is not registered as bankrupt in the CVR register. Its status is: active.
What is the bankruptcy risk of LIPLASOME PHARMA ApS?
Our model estimates a bankruptcy risk of 0.0% over the next 12 months (low risk), which is 0.0 times the average for Danish companies.
Who is the auditor of LIPLASOME PHARMA ApS?
LIPLASOME PHARMA ApS most recently used EY Godkendt Revisionspartnerselskab.
When was LIPLASOME PHARMA ApS founded?
LIPLASOME PHARMA ApS was founded on 8 February 2006.
What is the equity of LIPLASOME PHARMA ApS?
Equity was DKK 2.4m according to the annual report for the period ending 31 December 2025.
Source: the CVR register and annual reports published by the Danish Business Authority. The information is updated continuously.